Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fluorine-19 (19F) is the only naturally occurring stable isotope of fluorine and is a critical tool in diagnostic imaging and pharmacological research (PubChem, 2024). It possesses a nuclear spin of 1/2 and a high gyromagnetic ratio, which provides a sensitivity nearly 83% that of the hydrogen nucleus (1H) for Magnetic Resonance Imaging (MRI) (Ruiz-Cabello et al., 2011). A primary advantage of 19F is the near-absence of endogenous fluorine in soft tissues, which results in a negligible background signal and allows for high-contrast 'hot-spot' imaging of exogenous fluorinated probes (Tirotta et al., 2015). In the pharmaceutical industry, approximately 20-30% of modern drugs contain at least one fluorine atom, making 19F Nuclear Magnetic Resonance (NMR) an essential technique for studying drug metabolism, distribution, and binding (O'Hagan, 2010). While the 19F nucleus itself is not a therapeutic target, it is used to monitor the delivery and efficacy of drugs like 5-fluorouracil in cancer treatment (Ruiz-Cabello et al., 2011). Additionally, perfluorocarbon emulsions containing 19F are employed to label and track immune cells in vivo to study inflammation and immunotherapy responses (Tirotta et al., 2015). The lack of ionizing radiation and the ability to provide quantitative spatial information make 19F-based techniques highly valuable for clinical translation and drug development.
Fluorine-19 nuclei act as a signal source for magnetic resonance imaging (MRI) and spectroscopy (MRS) due to their 1/2 nuclear spin and high gyromagnetic ratio (Ruiz-Cabello et al., 2011). When placed in a static magnetic field and subjected to radiofrequency pulses at the Larmor frequency, these nuclei undergo resonance, allowing for the non-invasive detection, localization, and quantification of fluorinated compounds in biological systems without background interference from endogenous tissues (Tirotta et al., 2015).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fluorine-19 nucleus (19F).